Havemeyer Place LP Buys New Stake in Henry Schein, Inc. $HSIC

Havemeyer Place LP purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,499 shares of the company’s stock, valued at approximately $642,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its stake in shares of Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Henry Schein during the 1st quarter worth approximately $676,000. Cetera Investment Advisers boosted its holdings in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after acquiring an additional 637 shares during the period. Finally, First Trust Advisors LP grew its position in Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after acquiring an additional 1,669 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $78.05 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The firm’s 50-day simple moving average is $74.79 and its 200-day simple moving average is $76.01. The firm has a market cap of $8.89 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period last year, the firm earned $1.15 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts forecast that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director William K. Daniel purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total value of $98,630.45. Following the transaction, the chief executive officer owned 86,182 shares in the company, valued at $6,273,187.78. This trade represents a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.89% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on HSIC shares. Robert W. Baird set a $97.00 target price on Henry Schein in a research note on Wednesday, May 6th. Barrington Research set a $97.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Citigroup assumed coverage on Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price target for the company. BTIG Research began coverage on Henry Schein in a report on Thursday, April 16th. They set a “neutral” rating on the stock. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Henry Schein presently has an average rating of “Hold” and an average price target of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.